CCR2 genotype and disease progression in a treated population of HIV type 1-infected women.
Both antiretroviral therapy and the human coreceptor polymorphism CCR2-V64I slow progression of human immunodeficiency virus type 1 (HIV-1) disease. To examine the effect of V64I on disease progression in patients receiving therapy, we determined CCR2 genotypes in the Women's Interagency HIV Study cohort. We studied 2047 HIV-1-infected women, most of whom initiated treatment during the study. No association was seen between CCR2 genotype and either disease progression or therapeutic response, suggesting that the benefits of treatment most likely overshadow the salutary effects of the V64I polymorphism.
Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Sean
S
Philpott
Harold
H
Burger
Patrick M
PM
Tarwater
Ming
M
Lu
Stephen J
SJ
Gange
Kathryn
K
Anastos
Mardge
M
Cohen
Ruth M
RM
Greenblatt
Andrea
A
Kovacs
Howard
H
Minkoff
Mary
M
Young
Paolo
P
Miotti
Michelle
M
Dupuis
Barbara
B
Weiser
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018450:Disease Progression; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D015497:HIV-1; D006801:Humans; D011110:Polymorphism, Genetic; D054390:Receptors, CCR2; D019707:Receptors, Chemokine / Q000235:genetics*; D016019:Survival Analysis
C515334:CCR2 protein, human; D054390:Receptors, CCR2; D019707:Receptors, Chemokine